Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.50 |
| ▸ | YAP1 | P46937 | 3/20 | 0.50 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8517716 | 0.89 | GPR119 (0.45) | KDM4EPKMGPR119YAP1 | |
| SCHEMBL18280003 | 0.89 | ALDH1A1 (0.52) | GPR119YAP1STSTGFBR1 | |
| SCHEMBL18280185 | 0.88 | GPR119 (0.49) | KDM4EPKMGPR119 | |
| SCHEMBL18280123 | 0.88 | ALDH1A1 (0.54) | GPR119YAP1STSTGFBR1 | |
| SCHEMBL18280088 | 0.85 | GPR119 (0.54) | GPR119 | |
| SCHEMBL3923737 | 0.85 | KDM4E (0.64) | KDM4EPKMGPR119STS | |
| SCHEMBL28191245 | 0.85 | MET (0.53) | KDM4EPKMGPR119 | |
| SCHEMBL2448063 | 0.83 | FAAH (0.63) | KDM4EPKMGPR119YAP1STS | |
| SCHEMBL18279997 | 0.83 | KDM4E (0.59) | KDM4EPKMGPR119YAP1STS | |
| SCHEMBL16825188 | 0.82 | TGFBR1 (0.56) | KDM4EPKMSTSTGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301299-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180093977-A1 | Glycosidase Inhibitors | MERCK PATENT GMBH (DE) | 2018-04-05 | — | — | US | disclosed |
| US-9902712-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| EP-3083584-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF TISSUE FIBROSIS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2018-02-21 | — | — | EP | disclosed |
| CN-105143222-B | Glycosidase inhibitor | 默克专利有限公司 | 2018-02-02 | — | — | CN | disclosed |
| US-9879001-B2 | Glycosidase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | disclosed |
| CN-104725356-B | Nitrogen heterocyclic derivatives and application thereof in medicine | 广东东阳光药业有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20160355501-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-12-08 | — | — | US | disclosed |
| EP-3083584-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2016-10-26 | — | — | EP | disclosed |
| US-20160031871-A1 | Glycosidase Inhibitors | YU HENRY (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2970272-A1 | GLYCOSIDASE INHIBITORS | Merck Patent GmbH (DE) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015090232-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-25 | — | — | WO | disclosed |
| CN-104725356-A | Nitrogen heterocyclic derivatives and application thereof in medicine | GUANGDONG HEC PHARMACEUTICAL | 2015-06-24 | — | — | CN | disclosed |
| WO-2014159234-A1 | GLYCOSIDASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-10-02 | — | — | WO | disclosed |
| EP-2164493-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | Janssen Pharmaceutica, N.V. (BE) | 2010-03-24 | — | — | EP | disclosed |
| US-20090062294-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-05 | — | — | US | disclosed |
| WO-2008153752-A2 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-18 | — | — | WO | disclosed |
| US-20070021405-A1 | ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | US | disclosed |
| US-6303627-B1 | FOR THERAPY OF PHYSIOLOGICAL AND PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY | 2001-10-16 | — | — | US | disclosed |
| EP-0965587-A1 | Tetrahydropyridinyl- and piperidinyl Inhibitors of serotonin reuptake | ELI LILLY AND COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021405-A1 | ARYL- AND HETEROARYLPIPERIDINECARBOXYLATE-DERIVATIVES METHODS FOR THEIR PREPARATION AND USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, HRH2 | KDM4E 2229/4885PKM 3026/4885GPR119 39/4885 |
| US-20160031871-A1 | Glycosidase Inhibitors | GAA, BACE1, GBA3 | KDM4E 2273/4885PKM 1672/4885GPR119 103/4885 |
| US-20090062294-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | KDM4E 950/4885PKM 2680/4885GPR119 3/4885 |
| US-10301299-B2 | Glycosidase inhibitors | GAA, BACE1, GBA3 | KDM4E 2273/4885PKM 1672/4885GPR119 103/4885 |
| US-20180093977-A1 | Glycosidase Inhibitors | GAA, BACE1, GBA3 | KDM4E 2273/4885PKM 1672/4885GPR119 103/4885 |
| US-20160355501-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | TNNC1, IAPP, TNNI3 | KDM4E 4225/4885PKM 1064/4885GPR119 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.